Results 141 to 150 of about 1,571,650 (304)

Green and sustainable synthesis of magnetite from copper slag via citrate complexation for methylene blue dye removal from water

The Canadian Journal of Chemical Engineering, EarlyView.
Abstract This study proposes a novel, green, and sustainable method for synthesizing magnetic iron oxides from metallurgical copper slag (CS), leveraging its iron content as a valuable resource. Iron was extracted via acid leaching using edible citric acid (ECA), forming a citrate–iron complex (CSL), which was subsequently thermally decomposed at 300°C
Melisa Portilla‐Sangabriel, Karen Valencia García, Tania‐Ariadna García‐Mejía, Agileo Hernández‐Gordillo, Rosa‐María Ramírez‐Zamora   +4 more
wiley   +1 more source

Clinical behavior of a cohort of adult women with facial acne treated with combined oral contraceptive: ethinylestradiol 20 µg/dienogest 2 mg

International Journal of Women's Health, 2017
John Palacio-Cardona,1 Diana María Caicedo Borrero2 1Student Welfare Service – Health Area, Santiago de Cali University, 2Support for Research, Academic, Scientific and Technological Services (SEACIT), Cali, Colombia Abstract: Acne ...
Palacio-Cardona J, Caicedo Borrero DM
doaj  

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation

Clinical Pharmacology &Therapeutics, EarlyView.
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary, Robert Bies, Osei Boateng, Rachel Daley, Pierre Gashema, Mili Karina, Emily Njuguna, Sharon Nachman, Nathaniel Nkrumah, Carolyne Odula, Andrew Owen, Ethel D. Weld, Prajith Venkatasubramanian, Adeniyi Olagunju, on behalf of the Community of Practice for Long‐acting Therapeutics for Maternal and Paediatric Health, Rana Abutaima, Dorothy Akongo, Abdulnaser Alsharaa, Moherndran Archary, Shakir Atoyebi, Benoit Bestgen, Robert Bies, Osei Boateng, Andrew Butler, Edmund Capparelli, Rachel Daley, Layla Davies, Joelle Dountio, Henry Enzama, Pierre Gashema, Katila George, Dan Hawcutt, Rene Holm, Patrick Gad Iradukunda, Elodie Jambert, Mili Karina, Linda Lewis, Grace Miheso, Sebastien Morin, Andrew Morrison, Sharon Nachman, Shadia Nakalema, Emily Njunga, Nathaniel Nkrumah, Carolyne Odula‐Obonyo, Brenda Okware, Adeniyi Olagunju, Andrew Owen, Martina Penazzato, Natella Rakhmanina, Mphako Brighton Ratlabyana, Rachel Scott, Kimberly Struble, Andre‐Marie Tchouatieu, Catherine Unsworth, Prajith Venkatasubramanian, Catriona Waitt, Ethel Weld, Janine Winterbottom, Leena Zino   +59 more
wiley   +1 more source

Family planning methods among women in a vaginal microbicide feasibility study in rural KwaZulu-Natal, South Africa

This study investigated contraceptive use among women in rural KwaZulu-Natal, South Africa. Of 866 sexually active women not intending pregnancy and screened for a microbicide feasibility study, 466 (54%) reported currently using modern contraceptives ...
McGrath, N., Subramanian, L., Ndlovu, H., Gafos, M.   +3 more
core   +1 more source

Evaluation of pharmacokinetic interactions between long-acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084. [PDF]

J Int AIDS Soc
Marzinke MA, Hanscom B, Haines D, Scarsi KK, Agyei Y, Piwowar-Manning E, Hendrix CW, Gollings R, Rose S, Mathew C, Panchia R, Spooner E, Singh N, Bock P, Rinehart AR, Ford SL, Rooney JF, Soto-Torres L, Cohen MS, Hosseinipour MC, Delany-Moretlwe S, HPTN 084 Study Team.   +21 more
europepmc   +1 more source

A British Pharmacological Society Position Statement on Medications in Pregnancy and Lactation

British Journal of Clinical Pharmacology, EarlyView.
Agnesa Mustafa, Cleodie C. Swire, Reya V. Shah, Bernadette Jenner, Rory H. McLean, Muhammad Shamsher Ahmed, Adrie Bekker, Julia Zöllner, Rachel K. Scott, Robert R. Bies, Sara K. Quinney, Dagan O. Lonsdale, Emma Forton Magavern, Catriona Waitt, Anita Banerjee   +14 more
wiley   +1 more source

Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access

Clinical Pharmacology &Therapeutics, EarlyView.
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian, Moherndran Archary, Daniel B. Hawcutt, Rachel Daley, Edmund Capparelli, Adeniyi Olagunju   +5 more
wiley   +1 more source

Physiologically-based pharmacokinetic modeling of prominent oral contraceptive agents and applications in drug-drug interactions. [PDF]

CPT Pharmacometrics Syst Pharmacol
Lewis GJ, Ahire D, Taskar KS.
europepmc   +1 more source

Phase I Evaluation of Siltartoxatug, a First‐in‐Class Anti‐Tetanus Monoclonal Antibody: Safety, Pharmacokinetics and Pharmacodynamics in Healthy Australian and Chinese Populations

Clinical Pharmacology &Therapeutics, EarlyView.
Siltartoxatug, a first‐in‐class monoclonal antibody targeting tetanus toxin for post‐exposure prophylaxis, was evaluated in two phase I trials in Australian and Chinese healthy adults. In these randomized, double‐blind, placebo‐controlled, dose‐escalation studies, participants received a single intramuscular injection of siltartoxatug (10–250 μg/kg) or
Xinyu Liu, Zhigang Liu, Xiaohu Kuang, Yueming Wang, Xiaoyi Liu, Jiyuan Ding, Xia Zhou, Xin Zhou, Qianyu Liang, Meizhuo Zhang, Hao Zhao, Qingqing Tan, Weihong Zheng, Huaxin Liao, Charlotte Lemech, Wanmei Wang   +15 more
wiley   +1 more source

Exposure‐Response Analyses of Datopotamab Deruxtecan (Dato‐DXd), a TROP2‐Directed Antibody‐Drug Conjugate, in Advanced Non‐small Cell Lung Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Exposure‐response analyses supported a favorable benefit‐risk profile of Dato‐DXd at 6 mg/kg Q3W in patients with advanced nonsquamous NSCLC. Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell‐surface antigen‐2 (TROP2)‐directed antibody‐drug conjugate (ADC) that has demonstrated clinical activity in patients with NSCLC who have received prior ...
Ying Hong, Anna M. Mc Laughlin, Yuzhuo Pan, Sofia Friberg Hietala, Sophie Peigné, Michael Chargualaf, Zoey Tang, Diansong Zhou, Naoyuki Tajima, Malaz Abutarif, Tushar Garimella   +10 more
wiley   +1 more source